Corcept awards Justin Frederick Gunn 100,000 stock options

The options vest monthly over four years, contingent on continued service through each vesting date.

Rhea-AI Filing Summary

Corcept Therapeutics Inc. officer Justin Frederick Gunn, identified as President, Corcept Endocrinology, acquired a direct award of stock options covering 100,000 shares of common stock on October 1, 2026. The options have an exercise price of $114.025 per share and expire October 1, 2036. They become exercisable ratably in equal installments on each monthly anniversary over four years, subject to his continued service through each vesting date.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Gunn Justin Frederick

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. Exercisable ratably in equal installments on each monthly anniversary of October 1, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Key Figures

Options awarded: 100,000 options covering common stock Exercise price: $114.025 per share Vesting period: Four years +1 more

4 metrics

Options awarded 100,000 options covering common stock Awarded October 1, 2026

Exercise price $114.025 per share Stock options awarded October 1, 2026

Vesting period Four years Equal installments on each monthly anniversary, subject to continued service

Expiration date October 1, 2036 Stock options awarded October 1, 2026

Key Terms

exercisable ratably, equal installments, continued service

3 terms

exercisable ratably financial

"Exercisable ratably in equal installments"

equal installments financial

"in equal installments on each monthly anniversary"

continued service technical

"subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of the CORT option grant to Justin Frederick Gunn?

Justin Frederick Gunn received options covering 100,000 shares of common stock on October 1, 2026, with an exercise price of $114.025 per share and an expiration date of October 1, 2036.

How do Justin Frederick Gunn’s CORT options vest?

They become exercisable ratably in equal installments on each monthly anniversary of October 1, 2026, over a four-year period, subject to his continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 07:45 PM Accepted by SEC EDGAR 10/05/2026 - 07:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gunn Justin Frederick

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$114.025	10/01/2026		A		100,000		(1)	10/01/2036	Common Stock	100,000	$0.00	100,000	D

Explanation of Responses:

1. Exercisable ratably in equal installments on each monthly anniversary of October 1, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Justin Gunn	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)